Global Glucagon Like Peptide 2 Receptor Industry Insights: Market Size, Growth Analysis and Forecast
Report ID : 1322596 | Published : June 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Glucagon Like Peptide 2 Receptor Industry is categorized based on Drug Type (GLP-2 Agonists, Combination Therapies, Monotherapies) and Application (Diabetes Treatment, Obesity Management, Gastrointestinal Disorders, Others) and End-User (Hospitals, Specialty Clinics, Homecare Settings, Research Laboratories) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
The Glucagon Like Peptide 2 Receptor Industry was worth $1.2 billion in 2023 and is forecasted to reach $3.5 billion by 2033, growing at a CAGR of 11.5% over the period 2024-2033. This report covers various segments and analyzes the key trends and factors influencing the market significantly.
The Glucagon-Like Peptide 2 Receptor (GLP-2R) market has become one of the main points of interest in the broader scope of biopharmaceutical research and development. The upcoming pipeline of GLP-2R targeting drugs looks very promising due to the rising expectations for the treatment of short bowel syndrome and inflammatory bowel disease. The reimbursement policies alongside the economic burden of managing chronic conditions contributes to the growing interest towards the diseases. There is an increase in the use of chronic disease management programs which allows early intervention and decreases the total cost of treatment which brings a major opportunity to improve healthcare outcomes.
The metabolic roles of GLP-2 and its receptor are being examined profoundly in the fields of drug discovery and development and have resulted in a number of new research initiatives to explore novel GLP-2R-targeting drugs. This fueled the investment from other pharmaceutical companies which resulted in a wave of clinical trials and product developments. Apart from numerous opportunities, the market also has some challenges defining market access, strong clinical evidence to demonstrate the safety and efficacy of new solutions, and regulatory approval of the solutions. From such context, focusing on market dynamics including competitive tactics and changing consumer behavior will aid to grasp the complexities of the GLP-2R market efficiently.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Eli Lilly and Company, Novo Nordisk, Sanofi, Amgen, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Merck & Co., AstraZeneca, Takeda Pharmaceutical Company, Genentech |
| SEGMENTS COVERED |
By Drug Type - GLP-2 Agonists, Combination Therapies, Monotherapies
By Application - Diabetes Treatment, Obesity Management, Gastrointestinal Disorders, Others
By End-User - Hospitals, Specialty Clinics, Homecare Settings, Research Laboratories
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Glucagon Like Peptide 2 Receptor Industry Dynamics
The Glucagon Like Peptide 2 Receptor Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Glucagon Like Peptide 2 Receptor Industry Segmentations
Market Breakup by Drug Type
- Overview
- GLP-2 Agonists
- Combination Therapies
- Monotherapies
Market Breakup by Application
- Overview
- Diabetes Treatment
- Obesity Management
- Gastrointestinal Disorders
- Others
Market Breakup by End-User
- Overview
- Hospitals
- Specialty Clinics
- Homecare Settings
- Research Laboratories
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Glucagon Like Peptide 2 Receptor Industry
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Eli Lilly and Company
- Novo Nordisk
- Sanofi
- Amgen
- Boehringer Ingelheim
- Pfizer
- Bristol-Myers Squibb
- Merck & Co.
- AstraZeneca
- Takeda Pharmaceutical Company
- Genentech
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved